DK1372611T3 - Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer - Google Patents

Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer

Info

Publication number
DK1372611T3
DK1372611T3 DK02732526T DK02732526T DK1372611T3 DK 1372611 T3 DK1372611 T3 DK 1372611T3 DK 02732526 T DK02732526 T DK 02732526T DK 02732526 T DK02732526 T DK 02732526T DK 1372611 T3 DK1372611 T3 DK 1372611T3
Authority
DK
Denmark
Prior art keywords
surfactant
water
soluble
staurosporin
pharmaceutical composition
Prior art date
Application number
DK02732526T
Other languages
Danish (da)
English (en)
Inventor
Andreas Ebner
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001117049 external-priority patent/DE10117049A1/de
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1372611T3 publication Critical patent/DK1372611T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02732526T 2001-03-26 2002-03-26 Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer DK1372611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10114869 2001-03-26
DE2001117049 DE10117049A1 (de) 2001-04-05 2001-04-05 Zusammensetzung

Publications (1)

Publication Number Publication Date
DK1372611T3 true DK1372611T3 (da) 2006-09-18

Family

ID=26008913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02732526T DK1372611T3 (da) 2001-03-26 2002-03-26 Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer

Country Status (14)

Country Link
US (5) US20040077232A1 (enExample)
EP (1) EP1372611B1 (enExample)
JP (1) JP4330343B2 (enExample)
CN (1) CN100350911C (enExample)
AT (1) ATE326216T1 (enExample)
AU (1) AU2002304784A1 (enExample)
BR (1) BR0208306A (enExample)
CA (1) CA2439097C (enExample)
CY (1) CY1106159T1 (enExample)
DE (1) DE60211494T2 (enExample)
DK (1) DK1372611T3 (enExample)
ES (1) ES2261671T3 (enExample)
PT (1) PT1372611E (enExample)
WO (1) WO2002076432A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077883A2 (de) * 2002-03-15 2003-09-25 Kuyus Stiftung Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
WO2013024856A1 (ja) * 2011-08-17 2013-02-21 東レ株式会社 医療デバイスおよびその製造方法
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP2018501217A (ja) * 2014-12-02 2018-01-18 田辺三菱製薬株式会社 統合失調症を治療するための2−((1−(2(4−フルオロフェニル)−2−オキソエチル)ピペリジン−4−イル)メチル)イソインドリン−1−オン
KR20170084736A (ko) * 2016-01-12 2017-07-21 삼성디스플레이 주식회사 표시장치
CA3030422C (en) 2016-07-13 2021-10-26 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
US11642199B2 (en) * 2018-09-24 2023-05-09 3M Innovative Properties Company Dental appliance with cosmetic therapeutic aqueous solution
CN113797162B (zh) * 2020-06-17 2023-05-05 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
EP4637779A1 (en) * 2022-12-19 2025-10-29 Shenzhen Pharmacin Co., Ltd. Topical pharmaceutical compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3754082A (en) * 1970-06-11 1973-08-21 Richardson Merrell Inc Process and composition for botfly larvae eliminination
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
EP1004309A4 (en) * 1997-05-27 2001-01-17 Senju Pharma Co ISRAPAFANT-CONTAINING AQUEOUS COMPOSITIONS
TW546151B (en) * 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression

Also Published As

Publication number Publication date
CA2439097C (en) 2010-10-12
WO2002076432A3 (en) 2002-12-12
PT1372611E (pt) 2006-08-31
EP1372611A2 (en) 2004-01-02
CN100350911C (zh) 2007-11-28
CA2439097A1 (en) 2002-10-03
BR0208306A (pt) 2004-03-09
HK1061515A1 (en) 2004-09-24
US20080287417A1 (en) 2008-11-20
WO2002076432A2 (en) 2002-10-03
JP4330343B2 (ja) 2009-09-16
US20160287707A1 (en) 2016-10-06
AU2002304784A1 (en) 2002-10-08
EP1372611B1 (en) 2006-05-17
ATE326216T1 (de) 2006-06-15
CY1106159T1 (el) 2011-06-08
US20140018346A1 (en) 2014-01-16
US20040077232A1 (en) 2004-04-22
DE60211494D1 (de) 2006-06-22
US20140303145A1 (en) 2014-10-09
ES2261671T3 (es) 2006-11-16
JP2004534739A (ja) 2004-11-18
CN1499959A (zh) 2004-05-26
DE60211494T2 (de) 2006-10-12

Similar Documents

Publication Publication Date Title
PT1372611E (pt) Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
ATE292453T1 (de) Antivirale arznei
FI971986A7 (fi) Farmaseuttisia nanosuspensioita lääkeaineen antamiseen systeemeinä, joissa on kasvanut kyllästysliukoisuus ja liukenemisnopeus
AU4989997A (en) Soluble form osmotic dose delivery system
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
WO1998040069A3 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
HUP0500846A3 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
EP1391200A4 (en) DRUG
DK0998916T3 (da) Lægemidler til administration til slimhinden
ATE541562T1 (de) Ibuprofen-suspension
FI20012462A7 (fi) Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
BG108516A (en) Pharmaceutical formulation
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
EE200300192A (et) Guanidiini ja amidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline preparaatning eelravim
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
DK1189637T3 (da) Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
EP1426360A4 (en) 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICAMENTS CONTAINING THE SAME
DE50005082D1 (de) Verfahren zu Herstellung von PULVERFÖRMIGEn SOLUBILISATIONSHILFSSTOFFEn FÜR FESTE PHARMAZEUTISCHE DARREICHUNGSFORMEN